In Short
AI-driven drug discovery creates valuable intellectual property, but protection requires careful planning under UK law. Algorithms may be patentable if they solve a technical problem, while drug candidates must meet standard patent requirements with clear human inventorship. Trade secrets and licensing strategies also play a key role in protecting commercial value.
Tips for Businesses
Identify early which elements should be patented and which should remain confidential. Keep detailed records of human input into AI-assisted discoveries to support patent applications. Protect datasets and core algorithms with strong confidentiality measures, and ensure collaboration and licensing agreements clearly define ownership, improvements, and regulatory responsibilities.
Summary
This guide explains how UK life sciences SMEs can protect and commercialise intellectual property created through AI-driven drug discovery. It is prepared by LegalVision’s business lawyers, who specialise in advising clients on intellectual property protection and commercialisation in the UK life sciences sector.
The pharmaceutical industry is experiencing dramatic changes as a result of the recent advances in AI technology. Artificial intelligence is now capable of identifying potential drug candidates much more quickly, analysing vast datasets to predict molecular interactions, and optimising compound structures with precision. For UK small and medium-sized enterprises operating in this space, the competitive advantage lies not just in developing these AI-driven discoveries but in protecting them effectively. This article covers how life sciences businesses can protect and commercialise IP created through AI-driven drug discovery.
AI Algorithm Protection
The algorithms powering your drug discovery platform represent a significant investment and competitive advantage. In the UK, software and mathematical methods are generally not patentable on their own, but AI algorithms that produce a technical effect or solve a technical problem may qualify for patent protection. The key is demonstrating that your algorithm goes beyond mere data processing to achieve a concrete technical application in drug discovery.
Copyright automatically protects the source code of your AI system, but this offers limited commercial protection since it does not prevent others from developing algorithms that have similar functionality independently, provided the source code is different. If your goal is to protect your IP as comprehensively as possible, you could keep core algorithmic innovations as trade secrets, while pursuing patent protection for specific technical implementations that meet patentability criteria.
Drug Discovery Patents
Drug candidates identified through AI can present issues for patent eligibility. Traditional pharmaceutical patents cover novel chemical compounds, their manufacturing processes, and therapeutic applications. However, when AI generates these discoveries, it can be difficult to ascertain who the ‘inventor’ is, and therefore, meet the degree of human contribution required for patent validity.
Continue reading this article below the formCall 0808 196 8584 for urgent assistance.
Otherwise, complete this form, and we will contact you within one business day.
Trade Secret Strategies
Not all intellectual property belongs in a patent application. Trade secrets offer perpetual protection without the disclosure requirements and time limits inherent in patents. For AI drug discovery companies, certain elements often benefit more from trade secret protection than patenting.
Your datasets, particularly curated biological and chemical data that inform AI training, should typically remain trade secrets. These datasets represent years of compilation effort and provide ongoing competitive advantages that patents cannot.
You should ensure you have strong confidentiality measures to maintain trade secret status. This includes physical and digital security controls, restricted access protocols, and comprehensive non-disclosure agreements with employees, collaborators, and potential partners. If you conduct regular audits of your information security practices, this helps to demonstrate that you have taken reasonable steps to maintain secrecy, which UK courts require for trade secret enforcement.
IP Licensing Agreements
Licensing arrangements can accelerate commercialisation whilst generating revenue and expanding market reach. When negotiating licences for AI drug discovery intellectual property, make sure you address the following points.
Clearly define what is being licensed: the AI platform itself, specific drug candidates, or both. Exclusive licences command higher fees but limit your flexibility, whilst non-exclusive licences enable multiple revenue streams. Field-of-use restrictions can allow you to license your AI platform for different therapeutic areas to different partners.
Include provisions addressing improvements and derivative works. If licensees enhance your AI algorithms or discover new drug candidates using your platform, make sure it is clear upfront who owns these developments. Grant-back clauses requiring licensees to share improvements can be valuable, but may deter potential partners if they are too onerous.
Address regulatory and clinical development responsibilities explicitly. Drug development involves substantial ongoing investment beyond initial discovery. Clarify which party bears responsibility for regulatory approval processes and associated costs, and ensure milestone payments and royalty structures reflect the value created at each development stage.
LegalVision’s Trade Mark Essentials Guide provides valuable information for any business looking to register or enforce a trade mark.
Key Takeaways
AI algorithms may qualify for UK patent protection where they solve technical problems in drug discovery, but copyright alone provides limited commercial protection. Businesses should keep clear records of human involvement in AI-assisted discovery to support patent applications.
AI training datasets are often better protected as trade secrets, provided strong confidentiality measures are in place. However, trade secrets offer no protection against independent discovery or reverse engineering.
When licensing AI drug discovery IP, it is important to clearly define the scope of the licence, ownership of improvements, and responsibility for regulatory approval and associated costs.
Frequently Asked Questions
No. UK patent law requires human inventors. However, drugs and methods discovered using AI can be patented, provided there is sufficient human contribution to the inventive process. Your patent applications must clearly identify the human inventors and describe their creative contributions, even when AI performed significant analytical work.
This depends on several factors. If your algorithm is truly novel and produces specific technical effects in drug discovery, patent protection may be appropriate and could facilitate licensing. However, if the algorithm’s value lies in accumulated training data and continuous refinement, trade secret protection often proves more effective since it does not require disclosure and does not expire. Many companies protect the core drug candidates with patents while maintaining the AI platform as a trade secret.
Establish clear written agreements before sharing any confidential information or beginning collaborative work. These agreements should specify ownership of background intellectual property each party brings to the collaboration, ownership of newly created intellectual property, publication rights, and commercialisation responsibilities. Consider whether joint ownership serves your interests or whether exclusive ownership with cross-licences better protects your commercial position.
We appreciate your feedback – your submission has been successfully received.
